false --12-31 Q3 0001973056 0001973056 2024-01-01 2024-09-30 0001973056 BOWN:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2024-01-01 2024-09-30 0001973056 BOWN:OrdinarySharesParValue0.0001PerShareMember 2024-01-01 2024-09-30 0001973056 BOWN:RightsEachEntitlingHolderToOnetenthOfOneOrdinaryShareUponCompletionOfCompanysInitialBusinessCombinationMember 2024-01-01 2024-09-30 0001973056 2024-11-14 0001973056 2024-09-30 0001973056 2023-12-31 0001973056 us-gaap:NonrelatedPartyMember 2024-09-30 0001973056 us-gaap:NonrelatedPartyMember 2023-12-31 0001973056 us-gaap:RelatedPartyMember 2024-09-30 0001973056 us-gaap:RelatedPartyMember 2023-12-31 0001973056 2024-07-01 2024-09-30 0001973056 2023-07-01 2023-09-30 0001973056 2023-02-17 2023-09-30 0001973056 BOWN:RedeemableOrdinarySharesMember 2024-07-01 2024-09-30 0001973056 BOWN:RedeemableOrdinarySharesMember 2023-07-01 2023-09-30 0001973056 BOWN:RedeemableOrdinarySharesMember 2024-01-01 2024-09-30 0001973056 BOWN:RedeemableOrdinarySharesMember 2023-02-17 2023-09-30 0001973056 BOWN:NonRedeemableOrdinarySharesMember 2024-07-01 2024-09-30 0001973056 BOWN:NonRedeemableOrdinarySharesMember 2023-07-01 2023-09-30 0001973056 BOWN:NonRedeemableOrdinarySharesMember 2024-01-01 2024-09-30 0001973056 BOWN:NonRedeemableOrdinarySharesMember 2023-02-17 2023-09-30 0001973056 us-gaap:CommonStockMember 2023-12-31 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001973056 us-gaap:RetainedEarningsMember 2023-12-31 0001973056 us-gaap:CommonStockMember 2024-03-31 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001973056 us-gaap:RetainedEarningsMember 2024-03-31 0001973056 2024-03-31 0001973056 us-gaap:CommonStockMember 2024-06-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001973056 us-gaap:RetainedEarningsMember 2024-06-30 0001973056 2024-06-30 0001973056 us-gaap:CommonStockMember 2023-02-16 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-02-16 0001973056 us-gaap:RetainedEarningsMember 2023-02-16 0001973056 2023-02-16 0001973056 us-gaap:CommonStockMember 2023-06-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001973056 us-gaap:RetainedEarningsMember 2023-06-30 0001973056 2023-06-30 0001973056 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001973056 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001973056 2024-01-01 2024-03-31 0001973056 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001973056 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001973056 2024-04-01 2024-06-30 0001973056 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001973056 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001973056 us-gaap:CommonStockMember 2023-02-17 2023-03-31 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-02-17 2023-03-31 0001973056 us-gaap:RetainedEarningsMember 2023-02-17 2023-03-31 0001973056 2023-02-17 2023-03-31 0001973056 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001973056 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001973056 us-gaap:CommonStockMember 2024-09-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001973056 us-gaap:RetainedEarningsMember 2024-09-30 0001973056 us-gaap:CommonStockMember 2023-03-31 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001973056 us-gaap:RetainedEarningsMember 2023-03-31 0001973056 2023-03-31 0001973056 us-gaap:CommonStockMember 2023-09-30 0001973056 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001973056 us-gaap:RetainedEarningsMember 2023-09-30 0001973056 2023-09-30 0001973056 us-gaap:IPOMember 2023-07-14 2023-07-14 0001973056 us-gaap:IPOMember 2023-07-14 0001973056 us-gaap:PrivatePlacementMember 2023-07-14 2023-07-14 0001973056 us-gaap:PrivatePlacementMember 2023-07-14 0001973056 us-gaap:OverAllotmentOptionMember 2023-07-17 2023-07-17 0001973056 us-gaap:OverAllotmentOptionMember 2023-07-18 2023-07-18 0001973056 us-gaap:OverAllotmentOptionMember 2023-07-18 0001973056 us-gaap:PrivatePlacementMember 2023-07-18 2023-07-18 0001973056 us-gaap:IPOMember 2023-07-18 2023-07-18 0001973056 us-gaap:IPOMember 2023-07-18 0001973056 us-gaap:SubsequentEventMember 2024-10-07 0001973056 us-gaap:SubsequentEventMember BOWN:EarlyBirdCapitalMember 2024-10-07 0001973056 BOWN:MergerSharesMember BOWN:AgreementMember 2024-01-18 2024-01-18 0001973056 BOWN:EarnoutSharesMember BOWN:AgreementMember srt:MaximumMember 2024-01-18 2024-01-18 0001973056 BOWN:RedeemableSharesMember 2024-07-01 2024-09-30 0001973056 BOWN:NonRedeemableSharesMember 2024-07-01 2024-09-30 0001973056 BOWN:RedeemableSharesMember 2024-01-01 2024-09-30 0001973056 BOWN:NonRedeemableSharesMember 2024-01-01 2024-09-30 0001973056 BOWN:RedeemableSharesMember 2023-07-01 2023-09-30 0001973056 BOWN:NonRedeemableSharesMember 2023-07-01 2023-09-30 0001973056 BOWN:RedeemableSharesMember 2023-02-17 2023-09-30 0001973056 BOWN:NonRedeemableSharesMember 2023-02-17 2023-09-30 0001973056 us-gaap:IPOMember 2024-01-01 2024-09-30 0001973056 us-gaap:IPOMember 2024-09-30 0001973056 us-gaap:IPOMember 2023-12-31 0001973056 us-gaap:OverAllotmentOptionMember 2024-01-01 2024-09-30 0001973056 us-gaap:OverAllotmentOptionMember 2024-09-30 0001973056 us-gaap:OverAllotmentOptionMember srt:MaximumMember 2023-07-14 2023-07-14 0001973056 us-gaap:PrivatePlacementMember BOWN:SponsorsMember 2023-07-14 2023-07-14 0001973056 us-gaap:PrivatePlacementMember BOWN:EBCMember 2023-07-14 2023-07-14 0001973056 us-gaap:PrivatePlacementMember BOWN:UnderwritersMember 2023-07-14 2023-07-14 0001973056 BOWN:SponsorsMember 2023-02-27 2023-02-27 0001973056 BOWN:SponsorsMember us-gaap:OverAllotmentOptionMember 2023-02-27 2023-02-27 0001973056 BOWN:EBCMember 2023-03-15 2023-03-15 0001973056 BOWN:EBCMember 2023-03-15 0001973056 BOWN:PromissoryNoteMember BOWN:SponsorsMember 2023-02-27 0001973056 BOWN:PromissoryNoteMember BOWN:SponsorsMember 2023-02-27 2023-02-27 0001973056 BOWN:SponsorsMember us-gaap:IPOMember 2024-09-30 0001973056 us-gaap:RelatedPartyMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-09-30 0001973056 us-gaap:RelatedPartyMember BOWN:AccountingServicesExpenseMember 2024-09-30 0001973056 us-gaap:RelatedPartyMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-12-31 0001973056 us-gaap:RelatedPartyMember BOWN:AccountingServicesExpenseMember 2023-12-31 0001973056 BOWN:TenXGlobalCapitalMember 2023-02-17 2023-09-30 0001973056 BOWN:AccountingServiceAgreementMember 2024-07-01 2024-09-30 0001973056 BOWN:AccountingServiceAgreementMember 2023-07-01 2023-09-30 0001973056 BOWN:AccountingServiceAgreementMember 2024-01-01 2024-09-30 0001973056 BOWN:AccountingServiceAgreementMember 2023-02-17 2023-09-30 0001973056 BOWN:SponsorsMember srt:MaximumMember 2023-07-11 2023-07-11 0001973056 2023-03-15 2023-03-15 0001973056 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-15 0001973056 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-03-15 0001973056 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-15 0001973056 us-gaap:FairValueInputsLevel3Member BOWN:MeasurementInputProbabilityOfCompletionOfBusinessCombinationMember 2023-03-15 0001973056 BOWN:BusinessCombinationMarketingAgreementMember 2024-01-01 2024-09-30 0001973056 BOWN:BusinessCombinationMarketingAgreementMember 2024-09-30 0001973056 BOWN:QianzhiMember 2024-07-01 2024-09-30 0001973056 BOWN:QianzhiMember 2024-01-01 2024-09-30 0001973056 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001973056 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001973056 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001973056 us-gaap:SubsequentEventMember BOWN:EarlyBirdCapitalMember 2024-10-07 2024-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2024

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to __________

 

Commission File Number: 001-41741

 

Bowen Acquisition Corp

(Exact name of registrant as specified in its charter)

 

Cayman Islands   N/A
(State or other jurisdiction   (IRS Employer
of incorporation or organization)   Identification Number)

 

420 Lexington Ave, Suite 2446, New York, NY   10170
(Address of principal executive offices)   (Zip code)

 

(203) 998-5540

(Issuer’s telephone number including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

symbol(s)

  Name of each exchange on which registered
Units, each consisting of one ordinary share and one right   BOWNU   The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share   BOWN   The Nasdaq Stock Market LLC
Rights, each entitling the holder to one-tenth of one ordinary share upon the completion of the Company’s initial business combination   BOWNR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

  Large accelerated filer ☐ Accelerated filer ☐  
  Non-accelerated filer Smaller reporting company  
    Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☐

 

As of November 14, 2024, the registrant had 9,166,500 ordinary shares, $0.0001 par value, outstanding.

 

 

 

 

 

 

INDEX

 

Part I - Financial Information  
   
Item 1 – Financial Statements 3
   
Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 (Audited) 3
   
Consolidated Statements of Operations (Unaudited) 4
   
Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) 5
   
Consolidated Statements of Cash Flows (Unaudited) 7
   
Notes to Consolidated Unaudited Financial Statements 8
   
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
   
Item 3 – Quantitative and Qualitative Disclosures About Market Risk 24
   
Item 4 – Controls and Procedures 24
   
Part II - Other Information  
   
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 25
   
Item 5 – Other Information 26
   
Item 6 – Exhibits 26
   
Signatures 27

 

2

 

 

Part I - Financial Information

 

Item 1 – Financial Statements

 

BOWEN ACQUISITION CORP

CONSOLIDATED BALANCE SHEETS

 

   September 30, 2024  December 31, 2023
   (Unaudited)   
ASSETS          
           
Cash  $271,847   $426,913 
Prepaid expenses   25,152    79,481 
Total Current Assets   296,999    506,394 
Investment held in Trust Account   74,237,487    71,419,358 
Total Assets  $74,534,486   $71,925,752 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities:          
Accrued offering costs and expenses  $143,425   $78,610 
Accrued expenses - related party   65,695    25,250 
Payable to target   75,000    -   
Total Current Liabilities   284,120    103,860 
           
Total Liabilities   284,120    103,860 
           
Commitments and contingencies   -    - 
Ordinary shares subject to possible redemption, 6,900,000 shares at redemption value of $10.76 and $10.35 per share as of September 30, 2024 and December 31, 2023, respectively   74,237,487    71,419,358 
           
Shareholders’ Equity:          
Preferred shares, $0.0001 par value; 2,000,000 shares authorized; none issued and outstanding   -      -   
Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 2,266,500 shares issued and outstanding (excluding 6,900,000 shares subject to redemption on September 30, 2024  and December 31, 2023, respectively)   227    227 
Additional paid-in capital   -      -   
Retained earnings   12,652    402,307 
           
Total Shareholders’ Equity   12,879    402,534 
Total Liabilities and Shareholders’ Equity  $74,534,486   $71,925,752 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

3

 

 

BOWEN ACQUISITION CORP

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2024  2023      
  

Three Months Ended

September 30,

 

Nine Months Ended

September 30, 2024

 

For the Period from

February 17, 2023 (Inception) Through

September 30, 2023

   2024  2023      
Formation and operating costs  $127,429   $187,428   $389,655   $190,533 
Loss from operations   (127,429)   (187,428)   (389,655)   (190,533)
                     
Other Income:                    
Interest earned on investments held in trust account   952,787    760,871    2,818,129    760,871 
Total other income   952,787    760,871    2,818,129    760,871 
                     
Net income  $825,358   $573,444   $2,428,474   $570,338 
                     
Weighted average common stock outstanding, common stock subject to possible redemption   6,900,000    5,885,870    6,900,000    2,506,944 
Basic and diluted net income per share, common stock subject to redemption  $0.12   $0.46   $0.37   $1.60 
Weighted average common stock outstanding, common stock, non-redeemable   2,266,500    2,214,049    2,266,500    2,023,299 
Basic and diluted net loss per share, common stock, non-redeemable  $(0.01)  $(0.95)  $(0.04)  $(1.70)

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

4

 

 

BOWEN ACQUISITION CORP

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(UNAUDITED)

 

FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024

 

   Shares   Amount   Capital   Earnings   Equity 
   Ordinary Shares   Additional Paid-in   Retained   Total Shareholders’ 
   Shares   Amount   Capital   Earnings   Equity 
Balance as of January 1, 2024   2,266,500   $227   $-   $402,307   $402,534 
                          
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account)   -    -    -    (923,492)   (923,492)
Net income   -    -    -   $786,362    786,362 
                          
Balance as of March 31, 2024   2,266,500   $227   $-   $265,177   $265,404 
                          
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account)   -    -    

 

-

    (941,850)   (941,850)
Net income   -    -    -   $816,754    816,754 
                          
Balance as of June 30, 2024   2,266,500   $227   $-   $140,081   $140,308 
                          
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account)   -    -    -    (952,787)   (952,787)
Net income   -    -           -   $825,358    825,358 
                          
Balance as of September 30, 2024   2,266,500   $227   $-   $12,652   $12,879 

 

5

 

 

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023 AND THE PERIOD FROM FEBURARY 17, 2023 (INCEPTION) THROUGH SEPTEMBER 30, 2023

 

  

Ordinary

Shares

  

Additional

Paid-in

   Retained Earnings (Accumulated  

Total

Shareholders’

 
   Shares   Amount   Capital   Deficit)   Equity 
Balance on February 17, 2023 (inception)   -   $-   $-   $-   $- 
Issuance of ordinary shares to Sponsor   1,725,000    173    24,827    -    25,000 
Issuance of ordinary shares to Underwriter   180,000    18    1,015,982    -    1,016,000 
Net loss   -    -    -    (3,105)   (3,105)
                          
Balance as of March 31, 2023   1,905,000    191    1,040,809    (3,105)   1,037,895 
                          
Balance as of June 30, 2023   1,905,000   $191   $1,040,809   $(3,105)  $1,037,895 
                          
Proceeds from sale of public units   6,000,000    600    59,999,400    -    60,000,000 
Proceeds from over-allotment   900,000    90    8,999,910    -    9,000,000 
Sale of Private Units   330,000    33    3,299,967    -    3,300,000 
Over-allotment of Private Units   31,500    3    314,997    -    315,000 
Underwriter’s commission on sale of Public Units   -    -    (1,500,000)   -    (1,500,000)
Underwriter’s commission on Over-allotment   -    -    (225,000)   -    (225,000)
Other offering costs   -    -    (1,518,898)   -    (1,518,898)
Initial measurement of Ordinary shares Subject to redemption under ASC 480-10-S99 against additional paid-in capital   (6,900,000)   (690)   (65,235,677)   -    (65,236,367)
Allocation of offering costs to ordinary shares subject to redemption   -    -    3,066,958    -    3,066,958 
Deduction for increase of carrying value of redeemable shares   -    -    (7,520,591)   -    (7,520,591)
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account)   -    -    (721,875)   (38,996)   (760,871)
Net income   -    -    -    573,444    573,444 
                          
Balance as of September 30, 2023   2,266,500   $227   $-   $531,343   $531,570 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

6

 

 

BOWEN ACQUISITION CORP

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

  

For the Nine

Months Ended

September 30, 2024

 

For the Period from

February 17, 2023

(Inception) Through

September 30, 2023

Cash flows from operating activities:          
Net income  $2,428,474   $570,338 
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Income earned on investment held in Trust Account   (2,818,129)   (760,871)
Changes in current assets and liabilities:          
Accrued offering costs and expenses   160,094    93,383 
Accrued expenses - related party   40,445    -   
Prepaid Expenses   34,050    (120,720)
Net cash used in operating activities   (155,066)   (217,870)
           
Cash flows from investing activities:          
Investment held in Trust Account   -      (69,690,000)
Net cash used in investing activities   -      (69,690,000)
           
Cash flows from financing activities:          
Proceeds from issuance of founder shares   -      2,520 
Proceeds from sale of ordinary shares   -      69,000,000 
Proceeds from Private Placement   -      3,615,000 
Payments of underwriter’s discount   -      (1,725,000)
Proceeds from Private Placement   -      (151,318)
Payment of offering costs   -      (332,204)
Net cash provided by financing activities   -      70,408,998 
           
Net change in cash   (155,066)   501,128 
Cash at beginning of period   426,913    -   
Cash at the end of period  $271,847   $501,128 
           
Supplemental disclosure of noncash financing activities          
           
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)  $2,818,129   $760,871 
Offering cost paid by target company  $75,000   $- 
Deferred offering costs paid by Sponsor in exchange for issuance of ordinary shares  $-     $25,000 
Deferred offering costs adjusted from prepaid expenses  $-     $894 
Deferred offering costs charged to APIC  $-     $1,518,898 
Reclassification of ordinary shares subject to redemption  $-     $65,236,367 
Allocation of offering costs to ordinary shares subject to redemption  $-     $3,066,958 
Remeasurement adjustment on ordinary shares subject to possible redemption  $-     $7,520,591 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

7

 

 

BOWEN ACQUISITION CORP

UNAUDITED Notes to the CONSOLIDATED financial statements

 

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Organizational and General

 

Bowen Acquisition Corp (the “Company”) was incorporated in the Cayman Islands on February 17, 2023. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (the “Business Combination”).

 

The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

 

The Company’s sponsors are Createcharm Holdings Ltd., a British Virgin Islands company, and Bowen Holding LP, a Delaware limited partnership (the “Sponsors”). As of September 30, 2024, the Company had not commenced any operations. All activities for the period from February 17, 2023 (inception) through September 30, 2024 relate to the Company’s formation, the initial public offering (“IPO”) and initial business combination, which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company is generating non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.

 

The registration statement for the Company’s IPO (the “Registration Statement”) was declared effective on July 11, 2023. On July 14, 2023, the Company consummated the IPO of 6,000,000 of its units (“Public Units”). Each Public Unit consists of one ordinary share, $0.0001 par value (“Ordinary Shares”), of the Company and one right (“Rights”), each Right entitling the holder thereof to receive one-tenth of one ordinary share upon the completion of the Company’s initial business combination. The Public Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000.

 

Simultaneously with the consummation of the IPO, the Company consummated the private placement (“Private Placement”) of 330,000 units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit, generating total proceeds of $3,300,000. The Private Placement Units were purchased by Createcharm Holdings Ltd, one of the Company’s sponsors, and EarlyBirdCapital, Inc. (“EBC”), the representative of the underwriters in the IPO. The Private Placement Units are identical to the Units included in the Public Units sold in the IPO. The purchasers of the Private Placement Units have agreed not to transfer, assign or sell any of the Private Placement Units or Ordinary Shares or Rights underlying the Private Placement Units (except to certain transferees) until after the completion of the Company’s initial Business Combination.

 

8

 

 

On July 17, 2023, the underwriters exercised their over-allotment option in full to purchase an additional 900,000 Units. As a result, on July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. In connection with this sale, Createcharm Holdings Ltd. and EBC also purchased an additional 31,500 Private Placement Units from the Company.

 

As of July 18, 2023, transaction costs amounted to $3,318,898 consisting of $1,725,000 of cash underwriting fees and $1,593,898 of other offering costs. These costs were charged to additional paid-in capital or accumulated deficit to the extent additional paid-in capital is fully depleted upon completion of the IPO.

 

The Company will have until 18 months from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company has not completed a Business Combination within the Combination Period and shareholders have not otherwise amended the Amended and Restated Memorandum and Articles of Association to extend this period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned and not previously released to us to pay the Company’s taxes, if any (less certain amount of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 

Effective as of October 7, 2024, the Company notified the trustee of the Trust Account that it was extending the time to consummate an initial Business Combination from October 14, 2024 to January 14, 2025. Effective as of October 14, 2024, Shenzhen Qianzhi (as defined below) and EarlyBirdCapital, two designees of the Sponsors, loaned the Company an aggregate of $690,000, which funds were deposited into the Trust Account for such extension. The loans are evidenced by promissory notes (the “Notes”) issued by the Company to the designees. The Notes bear no interest and are repayable in full upon consummation of a Business Combination. In connection with the loans, one of the Sponsors transferred 30,000 of its Founder Shares to EarlyBirdCapital.

 

On November 20, 2023, a wholly-owned subsidiary of the Company, Bowen Merger Sub (“Merger Sub”) was formed for the purpose of entering into a business combination agreement. See “Proposed Business Combination” below.

 

Proposed Business Combination

 

On January 18, 2024, the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with (i) Bowen Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of the Company (“Merger Sub”), (ii) Shenzhen Qianzhi BioTechnology Co. Ltd., a company incorporated in the People’s Republic of China and a wholly owned subsidiary of NewCo (as defined below) (“Shenzhen Qianzhi”or “Qianzhi”), and (iii) Qianzhi Group Holding (Cayman) Limited, a newly formed Cayman Islands company (“NewCo,” and collectively with the Company, Merger Sub and Shenzhen Qianzhi, the “Parties”, each a “Party”).

 

9

 

 

Pursuant to the Agreement, at the closing of the business combination, Merger Sub will merge with and into NewCo (the “Merger”), with NewCo being the surviving company of the Merger (“Surviving Company”) and becoming a wholly owned subsidiary of the Company. In the Merger, the holders (the “NewCo Shareholders”) of the ordinary shares of NewCo (“NewCo Ordinary Shares”) will receive ordinary shares of the Company (“Parent Ordinary Shares”).

 

Pursuant to the Agreement, at the effective time of the Merger (the “Effective Time”), all of NewCo Ordinary Shares issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive an aggregate of (a) 7,246,377 Parent Ordinary Shares (the “Merger Shares”), and (b) the right to receive earnout consideration of up to an aggregate of 1,400,000 Parent Ordinary Shares (the “Earnout Shares”).

 

Going Concern Consideration

 

As of September 30, 2024, the Company had cash of $271,847 and a working capital of $12,879. The Company has incurred and expects to continue to incur significant professional costs to remain as a public traded company and to incur transaction costs in pursuit of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management believes that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period and such period is not extended, there will be a liquidation and subsequent dissolution. As a result, management has determined that such additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statement does not include any adjustments that might result from the outcome of the uncertainty.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the period ended September 30, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024. All intercompany accounts and transactions are eliminated upon consolidation. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024.

 

10

 

 

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of the consolidated financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and cash equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had a cash balance of $271,847 and $426,913 as of September 30, 2024 and December 31, 2023, respectively. The Company had no cash equivalents as of September 30, 2024 and December 31, 2023.

 

Investments Held in Trust Account

 

The Company’s portfolio of investments held in the Trust Account is comprised of investments only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2024 and December 31, 2023, the Trust Account had balance of $74,237,487 and $71,419,358, respectively. The interest and dividend income earned from the Trust Account totaled $952,787 and $2,818,129 for three and nine months ended September 30, 2024, respectively, which were fully reinvested into the Trust Account as earned and unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Consolidated Statements of Cash Flows.

 

11

 

 

Offering Costs

 

Offering costs consist of legal and other costs (including underwriting discounts and commissions) incurred through the balance sheet date that are directly related to the IPO and that were charged to shareholders’ equity upon the completion of the IPO on July 14, 2023.

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2024 and December 31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position.

 

There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements.

 

Net Income (Loss) per Ordinary Share

 

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

 

12

 

 

The net income (loss) per share presented in the statements of operations is based on the following:

 

 

   2024  2023  September 30,
2024
  September 30,
2023
   Three Months Ended September 30,  Nine Months Ended  For the Period from February 17, 2023 through
   2024  2023  September 30,
2024
  September 30,
2023
Net income (loss)  $825,358   $573,444   $2,428,474   $570,338 
Accretion of temporary equity into redemption value (interest earned)   (952,787)   (760,871)   (2,818,129)   (760,871)
Accretion of temporary equity into redemption value   -      (7,520,591)   -      (7,520,591)
Net loss including accretion of equity into redemption value  $(127,429)  $(7,708,018)  $(389,655)  $(7,711,124)

 

 

   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
   For Three Months Ended
September 30, 2024
  For Nine Months Ended
September 30, 2024
  For Three Months Ended
September 30, 2023
  For the Period from
February 17, 2023 through
September 30, 2023
   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
Particulars   Shares    Shares    Shares    Shares    Shares    Shares    Shares    Shares 
Basic and diluted net income/(loss) per share:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Ownership percentage   75%   25%   75%   25%   73%   27%   55%   45%
Numerators:                                        
Allocation of net loss including accretion of temporary equity   (95,921)   (31,508)   (293,309)   (96,346)   (5,601,092)   (2,106,926)   (4,267,179)   (3,443,945)
Interest earned on investment held in trust account   952,787    -      2,818,129    -      760,871    -      760,871    -   
Accretion of temporary equity to redemption value   -      -      -      -      7,520,591    -      7,520,591    -   
Allocation of net income/(loss)   856,866    (31,508)   2,524,820    (96,346)   2,680,370    (2,106,926)   4,014,283    (3,443,945)
Denominators:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Basic and diluted net income/(loss) per share  $0.12   $(0.01)  $0.37   $(0.04)  $0.46   $(0.95)  $1.60   $(1.70)

 

13

 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Ordinary Shares Subject to Possible Redemption

 

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

 

At September 30, 2024, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:

 

Public offering proceeds  $60,000,000 
Less:     
Proceeds allocated to Public Rights   (3,272,724)
Allocation of offering costs related to redeemable shares   (2,925,140)
Plus:     
Accretion of carrying value to redemption value   6,797,864 
Ordinary shares subject to possible redemption   60,600,000 
      
Over-allotment     
Plus:     
Over-allotment proceeds   9,000,000 
Less:     
Proceeds allocated to Public Rights   (490,909)
Allocation of offering costs related to redeemable shares   (212,727)
Plus:     
Accretion of carrying value to redemption value   793,636 
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   1,729,358 
Ordinary shares subject to possible redemption, December 31, 2023  $71,419,358 
Plus:     
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   2,818,129 
Ordinary shares subject to possible redemption, September 30, 2024  $74,237,487 

 

14

 

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 

NOTE 3 — INITIAL PUBLIC OFFERING

 

On July 14, 2023, the Company sold 6,000,000 Units at a price of $10.00 per Unit. Each Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. Ten Public Rights will entitle the holder to one ordinary share (see Note 7). The Company will not issue fractional shares and only whole shares will trade, so unless a holder purchased units in multiples of tens, such holder will not be able to receive or trade the fractional shares underlying the rights. The Company also granted the underwriters a 45-day option to purchase up to an additional 900,000 units to cover over-allotments. The over-allotment was subsequently fully exercised on July 17, 2023. See Note 1 for further details.

 

The Company incurred $75,000 Nasdaq delayed entry fee during the IPO in 2023 and this balance was subsequently paid by Qianzhi which is the target company. As of September 30, 2024, this balance is recorded as “Payable to target” on the consolidated balance sheet.

 

NOTE 4 — PRIVATE PLACEMENTS

 

The Sponsors and EBC had agreed to purchase an aggregate of 330,000 Private Placement Units (312,000 Private Placement Units to be purchased by the Sponsors and 18,000 Private Placement Units to be purchased by EBC or its designees), or 361,500 Private Placement Units if the underwriters’ over-allotment is exercised in full, at a price of $10.00 per Private Placement Unit ($3,300,000, or an aggregate of $3,615,000 if the underwriters’ over-allotment is exercised in full) from the Company in a private placement that will occur simultaneously with the closing of the Initial Public Offering.

 

Simultaneously with the closing of the IPO on July 14, 2023, the Company consummated the private sale of 330,000 Private Placement Units. Each Private Placement Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. The proceeds from the sale of the Private Placement Units were added to the net proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). The Private Placement Units (including the underlying securities) will not be transferable, assignable, or salable until the completion of a Business Combination, subject to certain exceptions.

 

On July 17, 2023, the underwriters exercised the over-allotment option in full. See Note 1 for more details.

 

15

 

 

NOTE 5 — RELATED PARTIES

 

Founder Shares and EBC Founder Shares

 

On February 27, 2023, the Sponsors received 1,725,000 of the Company’s ordinary shares (“Founder Shares”) in exchange for $25,000 paid for offering costs borne by the Sponsors. Up to 225,000 of such Founder Shares were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full. On July 17, 2023, the underwriters exercised their over-allotment option in full.

 

On March 15, 2023, the Company issued to EBC 180,000 ordinary shares (“EBC founder shares”) for a purchase price of $0.014 per share and an aggregate purchase price of $2,520. The EBC founder shares are deemed to be underwriters’ compensation by FINRA pursuant to Rule 5110 of the FINRA Manual. The Company estimated the fair value of the EBC founder shares to be approximately $1,016,000 or $5.65 per share using the Black-Scholes option pricing model. The Company accounted for the difference between the par value and fair value of the shares as offering cost.

 

The fair value of the EBC founder shares was estimated at March 15, 2023. The Company used the following assumptions to estimate the fair value of EBC founder shares using Level 3 fair value measurements inputs at the measurement date:

 

 

Time to expiration   1.84 
Risk-free rate   4.0%
Volatility   5.0%
Dividend yield   0.0%
Probability of completion of business combination   60.0%

 

The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) six months after the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction after an initial Business Combination that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property. EBC has also agreed, subject to exceptions, that the EBC founder shares cannot be sold, transferred or assigned, until the consummation of an initial business combination.

 

16

 

 

Promissory Note — Related Party

 

On February 27, 2023, the Sponsors issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. The Promissory Note was non-interest bearing and payable on the earlier of (i) December 31, 2023, or (ii) the consummation of the IPO. The Promissory Note expired on July 14, 2023.

 

Underwriting Agreement

 

The Company granted the underwriters a 45-day option from the date of IPO to purchase up to 900,000 additional Units to cover over-allotments, at the IPO price less the underwriting discounts and commissions.

 

The underwriters were entitled to a cash underwriting discount of $0.25 per Unit, or $1,500,000 in the aggregate (or $1,725,000 in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the IPO.

 

On July 17, 2023, the underwriters exercised the over-allotment option in full to purchase 900,000 Units. As a result, on July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds to the Company of $9,000,000.

 

Due to Related Party

 

The Sponsors paid certain formation, operating or offering costs on behalf of the Company. These amounts were due on demand and non-interest bearing. Before the IPO, the Sponsors had paid $151,318 on behalf of the Company for expenses related to IPO, which was fully repaid upon closing of the IPO on July 14, 2023 out of the offering proceeds held in trust account.

 

As of September 30, 2024, the total accrued expenses due to related parties was $65,695, which includes $60,000 payable for administration fee and $5,695 payable for accounting related service fee. As of December 31, 2023, the total accrued expenses due to related parties was $25,250, which include $20,000 payable for administration fee and $5,250 payable for accounting service fee. See following paragraphs for details.

 

Initial Accounting Service Fee

 

The Company has engaged TenX Global Capital, a related party of the Company, to assist in the preparation of financial statements and other accounting consulting services.

 

This initial accounting service fee was only related with the initial accounting preparation which was incurred in the period from February 17, 2023 (inception) to September 30, 2023 with total amount of $20,000. There was no such cost in the subsequent periods.

 

Accounting Service Agreement

 

The Company has engaged TenX Global Capital, a related party of the Company, to assist in preparing quarterly and annual financial statements commencing following the consummation of the IPO. The Company has agreed to pay for these services at a fixed quarterly rate of $5,250 each quarter. For three months ended September 30, 2024 and 2023, service fees of $5,250 have been accrued for these services. For nine months ended September 30, 2024 and during the period from February 17, 2023 (inception) through September 30, 2023, service fee of $15,750 and $5,250 have been incurred for these services.

 

17

 

 

Administration Fee

 

Commencing on the effectiveness of the Registration Statement on July 11, 2023, an affiliate of the Sponsors will be allowed to charge the Company an allocable share of its overhead, up to $10,000 per month, until to the close of the Business Combination, to compensate it for the Company’s use of its office, utilities and personnel. Administration fee of $30,000 and $90,000 were incurred for the three and nine months ended September 30, 2024, respectively. For three months ended September 30, 2023 and the period from February 17, 2023 (inception) through September 30, 2023, an administration fee of $26,667 was recorded and paid.

 

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, EBC founder shares, Private Placement Units will be entitled to registration rights pursuant to a registration rights agreement dated on the effectiveness of the Registration Statement on July 11, 2023 requiring the Company to register such securities for resale. Subject to certain limitations set forth in such agreement, the holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Business Combination Marketing Agreement

 

The Company has engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation of its initial Business Combination in an amount of $2,415,000, equal to 3.5% of the gross proceeds of the IPO. In addition, the Company will pay EBC a service fee in an amount equal to 1.0% of the total consideration payable in the initial Business Combination if it introduces the Company to the target business with whom it completes an initial Business Combination and the amount will be payable in cash and is due at the closing date of the initial Business Combination. EBC did not introduce the Company to Qianzhi.

 

18

 

 

Business Combination Transaction Cost

 

The Company has engaged several service providers including legal and valuation services, specifically for business combination between the Company and Shenzhen Qianzhi BioTechnology Co. Ltd. (“Qianzhi”). Per the agreed terms, Qianzhi agreed to be responsible for all expenses incurred by the Company in connection with business combination. During the three months ended September 30, 2024, $73,467 of business combination related cost has been incurred and reimbursed by Qianzhi. During the nine months ended September 30, 2024, $325,469 of business combination related cost has been incurred and reimbursed by Qianzhi. This activity has been recorded on the net basis and no impact to financial statements.

 

NOTE 7 — SHAREHOLDERS’ EQUITY

 

Preferred Shares — The Company is authorized to issue 2,000,000 preferred shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.

 

Ordinary Shares — The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. On February 27, 2023, the Sponsors received 1,725,000 of the Founder Shares in exchange for $25,000 paid for offering costs borne by the Sponsors, of which an aggregate of up to 225,000 of such Founder Shares were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company’s issued and outstanding ordinary shares after the IPO (excluding shares underlying the Private Placement Units). No ordinary shares are subject to forfeiture since the over-allotment was fully exercised on July 17, 2023. As of September 30, 2024 and December 31, 2023, there were 2,266,500 ordinary shares issued and outstanding (excluding 6,900,000 shares subject to possible redemption).

 

Rights — Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of the initial Business Combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-tenth (1/10) of one ordinary share underlying each right upon consummation of the business combination. If the Company is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.

 

NOTE 8 — Fair Value Measurements

 

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

 

Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

 

19

 

 

Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

 

Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

 

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

 

 

Date  Trading Securities  Level   Fair Value 
September 30, 2024  Marketable securities held in the trust account   1   $74,534,487 
              
December 31, 2023  Marketable securities held in the trust account   1   $71,419,358 

 

NOTE 9 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Based upon this review, the Company identified the following subsequent event that would have required adjustment or disclosure in the financial statements.

 

Effective as of October 7, 2024, the Company notified the trustee of the Trust Account that it was extending the time to consummate an initial Business Combination from October 14, 2024 to January 14, 2025. Effective as of October 14, 2024, Shenzhen Qianzhi and EarlyBirdCapital, two designees of the Sponsors, loaned the Company an aggregate of $690,000, which funds were deposited into the Trust Account for such extension. The loans are evidenced by promissory notes (the “Notes”) issued by the Company to the designees. The Notes bear no interest and are repayable in full upon consummation of a Business Combination. In connection with the loans, one of the Sponsors transferred 30,000 of its Founder Shares to EarlyBirdCapital.   The value of the shares transferred is reflected as debt discount and fully amortized as interest expense over the life of the loan in accordance with ASC 835.

 

20

 

 

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

References to the “Company,” “our,” “us” or “we” refer to Bowen Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes related thereto. Certain information contained in the discussion and analysis set forth below includes forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.

 

Overview

 

We are a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While we intend to focus our search on businesses in Asia, we are not limited to a particular industry or geographic region for purposes of consummating an initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the private placement of the private units, the proceeds of the sale of our securities in connection with our initial business combination, our shares, debt or a combination of cash, stock and debt.

 

Results of Operations

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception through September 30, 2024 were organizational activities, those necessary to prepare for the IPO described below and identifying a target company for our initial Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the IPO. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a Business Combination.

 

For the three months ended September 30, 2024, we had a net income of $825,358, which consists of loss of $127,429 derived from operating costs including legal and professional service expense offset by income earned on Trust Account of $952,787.

 

For the nine months ended September 30, 2024, we had a net income of $2,428,474, which consists of loss of $389,655 derived from operating costs including legal and professional service expense offset by income earned on Trust Account of $2,818,129.

 

For the three months ended September 30, 2023, we had a net income of $573,443, which consists of loss of $187,428 derived from formation and operating costs offset by income earned on Trust Account of $760,871.

 

For the period from February 17, 2023 (inception) through September 30, 2023, we had a net income of $570,338, which consists of loss of $190,533 derived from formation and operating costs offset by income earned on Trust Account of $760,871.

 

Liquidity, Capital Resources and Going Concern

 

On July 14, 2023, we consummated our IPO of Units, at $10.00 per Unit, generating gross proceeds of $60,000,000. Simultaneously with the closing of our IPO, we consummated the sale of 330,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsors, generating total gross proceeds of $3,300,000.

 

On July 17, 2023, the underwriters exercised the over-allotment option in full to purchase 900,000 Units. As a result, on July 18, 2023, we sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. Simultaneously with the closing of the full exercise of the over-allotment option, we completed the private sale of an aggregate of 31,500 Private Placement Units, at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds of $315,000. Transaction costs amounted to $3,318,898 consisting of $1,725,000 of cash underwriting fees and $1,593,898  of other offering costs.

 

21

 

 

Following the closing of the IPO and the sale of over-allotment units, an amount of $69,690,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement was placed in a trust account. The funds held in the Trust Account may be invested in U.S. government securities with a maturity of 185 days or less. We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account, to complete our initial business combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

Prior to the completion of our initial business combination, we have available to us the approximately $700,000 of proceeds held outside the trust account. We will use these funds primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination, and to pay taxes to the extent the interest earned on the trust account is not sufficient to pay our taxes.

 

We do not believe we will need to raise additional funds following this offering in order to meet the expenditures required for operating our business.   However, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating an initial business combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial business combination. Moreover, we may need to obtain additional financing either to complete our initial business combination or because we become obligated to redeem a significant number of our public shares upon completion of our initial business combination, in which case we may issue additional securities or incur debt in connection with such business combination.

 

As of September 30, 2024, we had cash of $271,847 and a working capital of $12,879. The Company has incurred and expects to continue to incur significant professional costs to remain as a public traded company and to incur transaction costs in pursuit of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management believes that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period and such period is not extended, there will be a liquidation and subsequent dissolution. As a result, management has determined that such additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statement does not include any adjustments that might result from the outcome of the uncertainty.

 

Related Party Transactions

 

Please refer to Financial Statement Note 5 - Related Parties.

 

22

 

 

Other Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities reflected on our balance sheet.

 

Registration Rights

 

The holders of the Founder Shares, EBC founder shares, Private Placement Units will be entitled to registration rights pursuant to a registration rights agreement dated July 11, 2023 requiring the Company to register such securities for resale. Subject to certain limitations set forth in such agreement, the holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Business Combination Marketing Agreement

 

We have engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation of its initial Business Combination in an amount equal to 3.5% of the gross proceeds of the IPO. In addition, the Company will pay EBC a service fee in an amount equal to 1.0% of the total consideration payable in the initial Business Combination if it introduces the Company to the target business with whom it completes an initial Business Combination and the amount will be payable in cash and is due at the closing date of the initial Business Combination.

 

Critical Accounting Policies and Estimates

 

The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have not identified any critical accounting estimates and all the significant accounting policies are described in the Note 2 of this reviewed consolidated financial statements.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

 

23

 

 

Item 3 – Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

Item 4 – Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2024. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective due solely to the material weakness in our internal control over financial reporting related to the Company’s lack of qualified SEC reporting professional. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with US GAAP. Accordingly, management believes that the financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, result of operations and cash flows for the periods presented. Management intends to continue implement remediation steps to improve our disclosure controls and procedures and our internal control over financial reporting. Specifically, we intend to expand and improve our review process for complex securities and related accounting standards. We have improved this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

24

 

 

Part II - Other Information

 

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

 

On February 27, 2023, Bowen Holding LP acquired an aggregate of 1,725,000 ordinary shares for an aggregate purchase price of $25,000. Bowen Holding LP thereafter transferred an aggregate of 1,155,750 ordinary shares to Createcharm Holdings Ltd, our other sponsor. The Company also issued to EarlyBirdCapital, Inc. 180,000 ordinary shares for an aggregate purchase price of $2,520 on March 15, 2023. The issuance of the foregoing securities was exempt pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”).

 

On July 14, 2023, the Company consummated the Initial Public Offering of 6,000,000 Units. Each Unit consists of one Ordinary Share, $0.0001 par value, of the Company and one Right, each Right entitling the holder thereof to receive one-tenth of one Ordinary Share upon the completion of the Company’s initial business combination. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000. EarlyBirdCapital, Inc. acted as sole book-running manager of the Initial Public Offering and Revere Securities acted as co-manager of the Initial Public Offering. The securities in the offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-272076). The Securities and Exchange Commission declared the registration statement effective on July 11, 2023.

 

Simultaneously with the consummation of the Initial Public Offering, the Company consummated the Private Placement of 330,000 Private Placement Units at a price of $10.00 per Private Placement Unit, generating total proceeds of $3,300,000. The Private Placement Units were purchased by Createcharm Holdings Ltd and EarlyBirdCapital, Inc. The Private Placement Units are identical to the Units sold in the Initial Public Offering. The purchasers of the Private Placement Units have agreed not to transfer, assign or sell any of the Private Placement Units or underlying securities (except to certain transferees) until after the completion of the Company’s initial business combination. The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

 

On July 17, 2023, the underwriters exercised their over-allotment option in full to purchase an additional 900,000 Units. As a result, on July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. In connection with this sale, Createcharm Holdings Ltd and EarlyBirdCapital, Inc. also purchased an additional 31,500 Private Placement Units from the Company, generating gross proceeds of $315,000. The issuance of the additional Private Placement Units was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

 

As of July 18, 2023, an aggregate of $69,690,000 has been deposited in the trust account established with Continental Stock Transfer & Trust Company acting as trustee in connection with the Initial Public Offering ($10.10 per unit sold in the offering, including the over-allotment option).

 

We paid a total of $1,725,000 in underwriting discounts and commissions related to the Initial Public Offering.

 

For a description of the use of the proceeds generated in the Initial Public Offering, see Part I, Item 2 of this Form 10-Q.

 

25

 

 

Item 5 – Other Information

 

During the quarter ended September 30, 2024, no director or officer adopted or terminated any (i) “Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K intending to satisfy the affirmative defense conditions of Rule 10b5–1(c) or (ii) “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.

 

Item 6 – Exhibits

 

Exhibit No.   Description
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File. The cover page XBRL tags are embedded within the Inline XBRL document.

 

* Filed herewith

** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

26

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  BOWEN ACQUISITION CORP
     
Dated: November 14, 2024 By. /s/ Jiangang Luo
    Jiangang Luo
   

Chief Executive Officer

(Principal Executive Officer)

     
Dated: November 14, 2024 By. /s/ Jing Lu
    Jing Lu
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

27

 

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jiangang Luo, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Bowen Acquisition Corp;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    (b) (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
       
    (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 14, 2024 BOWEN ACQUISITION CORP
  (Registrant)
     
  By: /s/ Jiangang Luo
    Jiangang Luo
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jing Lu, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Bowen Acquisition Corp;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    (b) (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);
       
    (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 14, 2024 BOWEN ACQUISITION CORP
  (Registrant)
     
  By: /s/ Jing Lu
    Jing Lu
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bowen Acquisition Corp (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Dated: November 14, 2024 BOWEN ACQUISITION CORP
  (Registrant)
     
  By: /s/ Jiangang Luo
    Jiangang Luo
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bowen Acquisition Corp (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Dated: November 14, 2024 BOWEN ACQUISITION CORP
  (Registrant)
     
  By: /s/ Jing Lu
    Jing Lu
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

v3.24.3
Cover - $ / shares
9 Months Ended
Sep. 30, 2024
Nov. 14, 2024
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41741  
Entity Registrant Name Bowen Acquisition Corp  
Entity Central Index Key 0001973056  
Entity Incorporation, State or Country Code E9  
Entity Address, Address Line One 420 Lexington Ave  
Entity Address, Address Line Two Suite 2446  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10170  
City Area Code (203)  
Local Phone Number 998-5540  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company true  
Entity Common Stock, Shares Outstanding   9,166,500
Entity Listing, Par Value Per Share $ 0.0001  
Units, each consisting of one ordinary share and one right    
Title of 12(b) Security Units, each consisting of one ordinary share and one right  
Trading Symbol BOWNU  
Security Exchange Name NASDAQ  
Ordinary Shares, par value $0.0001 per share    
Title of 12(b) Security Ordinary Shares, par value $0.0001 per share  
Trading Symbol BOWN  
Security Exchange Name NASDAQ  
Rights, each entitling the holder to one-tenth of one ordinary share upon the completion of the Company’s initial business combination    
Title of 12(b) Security Rights, each entitling the holder to one-tenth of one ordinary share upon the completion of the Company’s initial business combination  
Trading Symbol BOWNR  
Security Exchange Name NASDAQ  
v3.24.3
Consolidated Balance Sheets - USD ($)
Sep. 30, 2024
Dec. 31, 2023
ASSETS    
Cash $ 271,847 $ 426,913
Prepaid expenses 25,152 79,481
Total Current Assets 296,999 506,394
Investment held in Trust Account 74,237,487 71,419,358
Total Assets 74,534,486 71,925,752
Current Liabilities:    
Payable to target 75,000
Total Current Liabilities 284,120 103,860
Total Liabilities 284,120 103,860
Commitments and contingencies
Ordinary shares subject to possible redemption, 6,900,000 shares at redemption value of $10.76 and $10.35 per share as of September 30, 2024 and December 31, 2023, respectively 74,237,487 71,419,358
Shareholders’ Equity:    
Preferred shares, $0.0001 par value; 2,000,000 shares authorized; none issued and outstanding
Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 2,266,500 shares issued and outstanding (excluding 6,900,000 shares subject to redemption on September 30, 2024  and December 31, 2023, respectively) 227 227
Additional paid-in capital
Retained earnings 12,652 402,307
Total Shareholders’ Equity 12,879 402,534
Total Liabilities and Shareholders’ Equity 74,534,486 71,925,752
Nonrelated Party [Member]    
Current Liabilities:    
Accrued expenses 143,425 78,610
Related Party [Member]    
Current Liabilities:    
Accrued expenses $ 65,695 $ 25,250
v3.24.3
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Ordinary shares subject to redemption 6,900,000 6,900,000
Ordinary shares redemption value per share $ 10.76 $ 10.35
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Ordinary stock, par value $ 0.0001 $ 0.0001
Ordinary stock, shares authorized 200,000,000 200,000,000
Ordinary stock, shares issued 2,266,500 2,266,500
Ordinary stock, shares outstanding 2,266,500 2,266,500
v3.24.3
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 7 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Formation and operating costs $ 127,429 $ 187,428 $ 190,533 $ 389,655
Loss from operations (127,429) (187,428) (190,533) (389,655)
Other Income:        
Interest earned on investments held in trust account 952,787 760,871 760,871 2,818,129
Total other income 952,787 760,871 760,871 2,818,129
Net income $ 825,358 $ 573,444 $ 570,338 $ 2,428,474
Redeemable Ordinary Shares [Member]        
Other Income:        
Basic weighted average common stock outstanding 6,900,000 5,885,870 2,506,944 6,900,000
Diluted weighted average common stock outstanding 6,900,000 5,885,870 2,506,944 6,900,000
Basic net income (loss) per share, common stock $ 0.12 $ 0.46 $ 1.60 $ 0.37
Diluted net income (loss) per share, common stock $ 0.12 $ 0.46 $ 1.60 $ 0.37
Non Redeemable Ordinary Shares [Member]        
Other Income:        
Basic weighted average common stock outstanding 2,266,500 2,214,049 2,023,299 2,266,500
Diluted weighted average common stock outstanding 2,266,500 2,214,049 2,023,299 2,266,500
Basic net income (loss) per share, common stock $ (0.01) $ (0.95) $ (1.70) $ (0.04)
Diluted net income (loss) per share, common stock $ (0.01) $ (0.95) $ (1.70) $ (0.04)
v3.24.3
Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Feb. 16, 2023
Balance, shares at Feb. 16, 2023      
Net income (loss) (3,105) (3,105)
Issuance of ordinary shares to Sponsor $ 173 24,827 25,000
Issuance of ordinary shares to Sponsor, shares 1,725,000      
Issuance of ordinary shares to Underwriter $ 18 1,015,982 1,016,000
Issuance of ordinary shares to Underwriter, shares 180,000      
Balance at Mar. 31, 2023 $ 191 1,040,809 (3,105) 1,037,895
Balance, shares at Mar. 31, 2023 1,905,000      
Balance at Feb. 16, 2023
Balance, shares at Feb. 16, 2023      
Net income (loss)       570,338
Balance at Sep. 30, 2023 $ 227 531,343 531,570
Balance, shares at Sep. 30, 2023 2,266,500      
Balance at Jun. 30, 2023 $ 191 1,040,809 (3,105) 1,037,895
Balance, shares at Jun. 30, 2023 1,905,000      
Net income (loss) 573,444 573,444
Proceeds from sale of public units $ 600 59,999,400 60,000,000
Proceeds from sale of public units, shares 6,000,000      
Proceeds from over-allotment $ 90 8,999,910 9,000,000
Proceeds from over-allotment, shares 900,000      
Sale of Private Units $ 33 3,299,967 3,300,000
Sale of Private Units, shares 330,000      
Over-allotment of Private Units $ 3 314,997 315,000
Over-allotment of Private Units, shares 31,500      
Underwriter’s commission on sale of Public Units (1,500,000) (1,500,000)
Underwriter’s commission on Over-allotment (225,000) (225,000)
Other offering costs (1,518,898) (1,518,898)
Initial measurement of Ordinary shares Subject to redemption under ASC 480-10-S99 against additional paid-in capital $ (690) (65,235,677) (65,236,367)
Initial measurement of Ordinary shares Subject to redemption under ASC 480-10-S99 against additional paid-in capital, shares (6,900,000)      
Allocation of offering costs to ordinary shares subject to redemption 3,066,958 3,066,958
Deduction for increase of carrying value of redeemable shares (7,520,591) (7,520,591)
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account) (721,875) (38,996) (760,871)
Balance at Sep. 30, 2023 $ 227 531,343 531,570
Balance, shares at Sep. 30, 2023 2,266,500      
Balance at Dec. 31, 2023 $ 227 402,307 402,534
Balance, shares at Dec. 31, 2023 2,266,500      
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account) (923,492) (923,492)
Net income (loss) 786,362 786,362
Balance at Mar. 31, 2024 $ 227 265,177 265,404
Balance, shares at Mar. 31, 2024 2,266,500      
Balance at Dec. 31, 2023 $ 227 402,307 402,534
Balance, shares at Dec. 31, 2023 2,266,500      
Net income (loss)       2,428,474
Balance at Sep. 30, 2024 $ 227 12,652 12,879
Balance, shares at Sep. 30, 2024 2,266,500      
Balance at Mar. 31, 2024 $ 227 265,177 265,404
Balance, shares at Mar. 31, 2024 2,266,500      
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account) (941,850) (941,850)
Net income (loss) 816,754 816,754
Balance at Jun. 30, 2024 $ 227 140,081 140,308
Balance, shares at Jun. 30, 2024 2,266,500      
Subsequent measurement of Common stock subject to possible redemption (interest earned on trust account) (952,787) (952,787)
Net income (loss) 825,358 825,358
Balance at Sep. 30, 2024 $ 227 $ 12,652 $ 12,879
Balance, shares at Sep. 30, 2024 2,266,500      
v3.24.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
7 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2024
Cash flows from operating activities:    
Net income $ 570,338 $ 2,428,474
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Income earned on investment held in Trust Account (760,871) (2,818,129)
Changes in current assets and liabilities:    
Accrued offering costs and expenses 93,383 160,094
Accrued expenses - related party 40,445
Prepaid Expenses (120,720) 34,050
Net cash used in operating activities (217,870) (155,066)
Cash flows from investing activities:    
Investment held in Trust Account (69,690,000)
Net cash used in investing activities (69,690,000)
Cash flows from financing activities:    
Proceeds from issuance of founder shares 2,520
Proceeds from sale of ordinary shares 69,000,000
Proceeds from Private Placement 3,615,000
Payments of underwriter’s discount (1,725,000)
Proceeds from Private Placement (151,318)
Payment of offering costs (332,204)
Net cash provided by financing activities 70,408,998
Net change in cash 501,128 (155,066)
Cash at beginning of period 426,913
Cash at the end of period 501,128 271,847
Supplemental disclosure of noncash financing activities    
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account) 760,871 2,818,129
Offering cost paid by target company 75,000
Deferred offering costs paid by Sponsor in exchange for issuance of ordinary shares 25,000
Deferred offering costs adjusted from prepaid expenses 894
Deferred offering costs charged to APIC 1,518,898
Reclassification of ordinary shares subject to redemption 65,236,367
Allocation of offering costs to ordinary shares subject to redemption 3,066,958
Remeasurement adjustment on ordinary shares subject to possible redemption $ 7,520,591
v3.24.3
Pay vs Performance Disclosure - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Pay vs Performance Disclosure [Table]              
Net Income (Loss) $ (3,105) $ 825,358 $ 816,754 $ 786,362 $ 573,444 $ 570,338 $ 2,428,474
v3.24.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual [Table]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
ORGANIZATION AND BUSINESS OPERATIONS
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND BUSINESS OPERATIONS

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

 

Organizational and General

 

Bowen Acquisition Corp (the “Company”) was incorporated in the Cayman Islands on February 17, 2023. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (the “Business Combination”).

 

The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

 

The Company’s sponsors are Createcharm Holdings Ltd., a British Virgin Islands company, and Bowen Holding LP, a Delaware limited partnership (the “Sponsors”). As of September 30, 2024, the Company had not commenced any operations. All activities for the period from February 17, 2023 (inception) through September 30, 2024 relate to the Company’s formation, the initial public offering (“IPO”) and initial business combination, which is described below. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company is generating non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.

 

The registration statement for the Company’s IPO (the “Registration Statement”) was declared effective on July 11, 2023. On July 14, 2023, the Company consummated the IPO of 6,000,000 of its units (“Public Units”). Each Public Unit consists of one ordinary share, $0.0001 par value (“Ordinary Shares”), of the Company and one right (“Rights”), each Right entitling the holder thereof to receive one-tenth of one ordinary share upon the completion of the Company’s initial business combination. The Public Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000.

 

Simultaneously with the consummation of the IPO, the Company consummated the private placement (“Private Placement”) of 330,000 units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit, generating total proceeds of $3,300,000. The Private Placement Units were purchased by Createcharm Holdings Ltd, one of the Company’s sponsors, and EarlyBirdCapital, Inc. (“EBC”), the representative of the underwriters in the IPO. The Private Placement Units are identical to the Units included in the Public Units sold in the IPO. The purchasers of the Private Placement Units have agreed not to transfer, assign or sell any of the Private Placement Units or Ordinary Shares or Rights underlying the Private Placement Units (except to certain transferees) until after the completion of the Company’s initial Business Combination.

 

 

On July 17, 2023, the underwriters exercised their over-allotment option in full to purchase an additional 900,000 Units. As a result, on July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. In connection with this sale, Createcharm Holdings Ltd. and EBC also purchased an additional 31,500 Private Placement Units from the Company.

 

As of July 18, 2023, transaction costs amounted to $3,318,898 consisting of $1,725,000 of cash underwriting fees and $1,593,898 of other offering costs. These costs were charged to additional paid-in capital or accumulated deficit to the extent additional paid-in capital is fully depleted upon completion of the IPO.

 

The Company will have until 18 months from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company has not completed a Business Combination within the Combination Period and shareholders have not otherwise amended the Amended and Restated Memorandum and Articles of Association to extend this period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned and not previously released to us to pay the Company’s taxes, if any (less certain amount of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 

Effective as of October 7, 2024, the Company notified the trustee of the Trust Account that it was extending the time to consummate an initial Business Combination from October 14, 2024 to January 14, 2025. Effective as of October 14, 2024, Shenzhen Qianzhi (as defined below) and EarlyBirdCapital, two designees of the Sponsors, loaned the Company an aggregate of $690,000, which funds were deposited into the Trust Account for such extension. The loans are evidenced by promissory notes (the “Notes”) issued by the Company to the designees. The Notes bear no interest and are repayable in full upon consummation of a Business Combination. In connection with the loans, one of the Sponsors transferred 30,000 of its Founder Shares to EarlyBirdCapital.

 

On November 20, 2023, a wholly-owned subsidiary of the Company, Bowen Merger Sub (“Merger Sub”) was formed for the purpose of entering into a business combination agreement. See “Proposed Business Combination” below.

 

Proposed Business Combination

 

On January 18, 2024, the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with (i) Bowen Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of the Company (“Merger Sub”), (ii) Shenzhen Qianzhi BioTechnology Co. Ltd., a company incorporated in the People’s Republic of China and a wholly owned subsidiary of NewCo (as defined below) (“Shenzhen Qianzhi”or “Qianzhi”), and (iii) Qianzhi Group Holding (Cayman) Limited, a newly formed Cayman Islands company (“NewCo,” and collectively with the Company, Merger Sub and Shenzhen Qianzhi, the “Parties”, each a “Party”).

 

 

Pursuant to the Agreement, at the closing of the business combination, Merger Sub will merge with and into NewCo (the “Merger”), with NewCo being the surviving company of the Merger (“Surviving Company”) and becoming a wholly owned subsidiary of the Company. In the Merger, the holders (the “NewCo Shareholders”) of the ordinary shares of NewCo (“NewCo Ordinary Shares”) will receive ordinary shares of the Company (“Parent Ordinary Shares”).

 

Pursuant to the Agreement, at the effective time of the Merger (the “Effective Time”), all of NewCo Ordinary Shares issued and outstanding immediately prior to the Effective Time will be automatically converted into the right to receive an aggregate of (a) 7,246,377 Parent Ordinary Shares (the “Merger Shares”), and (b) the right to receive earnout consideration of up to an aggregate of 1,400,000 Parent Ordinary Shares (the “Earnout Shares”).

 

Going Concern Consideration

 

As of September 30, 2024, the Company had cash of $271,847 and a working capital of $12,879. The Company has incurred and expects to continue to incur significant professional costs to remain as a public traded company and to incur transaction costs in pursuit of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management believes that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period and such period is not extended, there will be a liquidation and subsequent dissolution. As a result, management has determined that such additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statement does not include any adjustments that might result from the outcome of the uncertainty.

 

v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the period ended September 30, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024. All intercompany accounts and transactions are eliminated upon consolidation. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024.

 

 

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of the consolidated financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and cash equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had a cash balance of $271,847 and $426,913 as of September 30, 2024 and December 31, 2023, respectively. The Company had no cash equivalents as of September 30, 2024 and December 31, 2023.

 

Investments Held in Trust Account

 

The Company’s portfolio of investments held in the Trust Account is comprised of investments only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2024 and December 31, 2023, the Trust Account had balance of $74,237,487 and $71,419,358, respectively. The interest and dividend income earned from the Trust Account totaled $952,787 and $2,818,129 for three and nine months ended September 30, 2024, respectively, which were fully reinvested into the Trust Account as earned and unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Consolidated Statements of Cash Flows.

 

 

Offering Costs

 

Offering costs consist of legal and other costs (including underwriting discounts and commissions) incurred through the balance sheet date that are directly related to the IPO and that were charged to shareholders’ equity upon the completion of the IPO on July 14, 2023.

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2024 and December 31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position.

 

There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements.

 

Net Income (Loss) per Ordinary Share

 

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

 

 

The net income (loss) per share presented in the statements of operations is based on the following:

 

 

   2024  2023  September 30,
2024
  September 30,
2023
   Three Months Ended September 30,  Nine Months Ended  For the Period from February 17, 2023 through
   2024  2023  September 30,
2024
  September 30,
2023
Net income (loss)  $825,358   $573,444   $2,428,474   $570,338 
Accretion of temporary equity into redemption value (interest earned)   (952,787)   (760,871)   (2,818,129)   (760,871)
Accretion of temporary equity into redemption value   -      (7,520,591)   -      (7,520,591)
Net loss including accretion of equity into redemption value  $(127,429)  $(7,708,018)  $(389,655)  $(7,711,124)

 

 

   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
   For Three Months Ended
September 30, 2024
  For Nine Months Ended
September 30, 2024
  For Three Months Ended
September 30, 2023
  For the Period from
February 17, 2023 through
September 30, 2023
   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
Particulars   Shares    Shares    Shares    Shares    Shares    Shares    Shares    Shares 
Basic and diluted net income/(loss) per share:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Ownership percentage   75%   25%   75%   25%   73%   27%   55%   45%
Numerators:                                        
Allocation of net loss including accretion of temporary equity   (95,921)   (31,508)   (293,309)   (96,346)   (5,601,092)   (2,106,926)   (4,267,179)   (3,443,945)
Interest earned on investment held in trust account   952,787    -      2,818,129    -      760,871    -      760,871    -   
Accretion of temporary equity to redemption value   -      -      -      -      7,520,591    -      7,520,591    -   
Allocation of net income/(loss)   856,866    (31,508)   2,524,820    (96,346)   2,680,370    (2,106,926)   4,014,283    (3,443,945)
Denominators:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Basic and diluted net income/(loss) per share  $0.12   $(0.01)  $0.37   $(0.04)  $0.46   $(0.95)  $1.60   $(1.70)

 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Ordinary Shares Subject to Possible Redemption

 

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

 

At September 30, 2024, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:

 

Public offering proceeds  $60,000,000 
Less:     
Proceeds allocated to Public Rights   (3,272,724)
Allocation of offering costs related to redeemable shares   (2,925,140)
Plus:     
Accretion of carrying value to redemption value   6,797,864 
Ordinary shares subject to possible redemption   60,600,000 
      
Over-allotment     
Plus:     
Over-allotment proceeds   9,000,000 
Less:     
Proceeds allocated to Public Rights   (490,909)
Allocation of offering costs related to redeemable shares   (212,727)
Plus:     
Accretion of carrying value to redemption value   793,636 
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   1,729,358 
Ordinary shares subject to possible redemption, December 31, 2023  $71,419,358 
Plus:     
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   2,818,129 
Ordinary shares subject to possible redemption, September 30, 2024  $74,237,487 

 

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 

v3.24.3
INITIAL PUBLIC OFFERING
9 Months Ended
Sep. 30, 2024
Initial Public Offering  
INITIAL PUBLIC OFFERING

NOTE 3 — INITIAL PUBLIC OFFERING

 

On July 14, 2023, the Company sold 6,000,000 Units at a price of $10.00 per Unit. Each Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. Ten Public Rights will entitle the holder to one ordinary share (see Note 7). The Company will not issue fractional shares and only whole shares will trade, so unless a holder purchased units in multiples of tens, such holder will not be able to receive or trade the fractional shares underlying the rights. The Company also granted the underwriters a 45-day option to purchase up to an additional 900,000 units to cover over-allotments. The over-allotment was subsequently fully exercised on July 17, 2023. See Note 1 for further details.

 

The Company incurred $75,000 Nasdaq delayed entry fee during the IPO in 2023 and this balance was subsequently paid by Qianzhi which is the target company. As of September 30, 2024, this balance is recorded as “Payable to target” on the consolidated balance sheet.

 

v3.24.3
PRIVATE PLACEMENTS
9 Months Ended
Sep. 30, 2024
Private Placements  
PRIVATE PLACEMENTS

NOTE 4 — PRIVATE PLACEMENTS

 

The Sponsors and EBC had agreed to purchase an aggregate of 330,000 Private Placement Units (312,000 Private Placement Units to be purchased by the Sponsors and 18,000 Private Placement Units to be purchased by EBC or its designees), or 361,500 Private Placement Units if the underwriters’ over-allotment is exercised in full, at a price of $10.00 per Private Placement Unit ($3,300,000, or an aggregate of $3,615,000 if the underwriters’ over-allotment is exercised in full) from the Company in a private placement that will occur simultaneously with the closing of the Initial Public Offering.

 

Simultaneously with the closing of the IPO on July 14, 2023, the Company consummated the private sale of 330,000 Private Placement Units. Each Private Placement Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. The proceeds from the sale of the Private Placement Units were added to the net proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). The Private Placement Units (including the underlying securities) will not be transferable, assignable, or salable until the completion of a Business Combination, subject to certain exceptions.

 

On July 17, 2023, the underwriters exercised the over-allotment option in full. See Note 1 for more details.

 

 

v3.24.3
RELATED PARTIES
9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
RELATED PARTIES

NOTE 5 — RELATED PARTIES

 

Founder Shares and EBC Founder Shares

 

On February 27, 2023, the Sponsors received 1,725,000 of the Company’s ordinary shares (“Founder Shares”) in exchange for $25,000 paid for offering costs borne by the Sponsors. Up to 225,000 of such Founder Shares were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full. On July 17, 2023, the underwriters exercised their over-allotment option in full.

 

On March 15, 2023, the Company issued to EBC 180,000 ordinary shares (“EBC founder shares”) for a purchase price of $0.014 per share and an aggregate purchase price of $2,520. The EBC founder shares are deemed to be underwriters’ compensation by FINRA pursuant to Rule 5110 of the FINRA Manual. The Company estimated the fair value of the EBC founder shares to be approximately $1,016,000 or $5.65 per share using the Black-Scholes option pricing model. The Company accounted for the difference between the par value and fair value of the shares as offering cost.

 

The fair value of the EBC founder shares was estimated at March 15, 2023. The Company used the following assumptions to estimate the fair value of EBC founder shares using Level 3 fair value measurements inputs at the measurement date:

 

 

Time to expiration   1.84 
Risk-free rate   4.0%
Volatility   5.0%
Dividend yield   0.0%
Probability of completion of business combination   60.0%

 

The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) six months after the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction after an initial Business Combination that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property. EBC has also agreed, subject to exceptions, that the EBC founder shares cannot be sold, transferred or assigned, until the consummation of an initial business combination.

 

 

Promissory Note — Related Party

 

On February 27, 2023, the Sponsors issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. The Promissory Note was non-interest bearing and payable on the earlier of (i) December 31, 2023, or (ii) the consummation of the IPO. The Promissory Note expired on July 14, 2023.

 

Underwriting Agreement

 

The Company granted the underwriters a 45-day option from the date of IPO to purchase up to 900,000 additional Units to cover over-allotments, at the IPO price less the underwriting discounts and commissions.

 

The underwriters were entitled to a cash underwriting discount of $0.25 per Unit, or $1,500,000 in the aggregate (or $1,725,000 in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the IPO.

 

On July 17, 2023, the underwriters exercised the over-allotment option in full to purchase 900,000 Units. As a result, on July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds to the Company of $9,000,000.

 

Due to Related Party

 

The Sponsors paid certain formation, operating or offering costs on behalf of the Company. These amounts were due on demand and non-interest bearing. Before the IPO, the Sponsors had paid $151,318 on behalf of the Company for expenses related to IPO, which was fully repaid upon closing of the IPO on July 14, 2023 out of the offering proceeds held in trust account.

 

As of September 30, 2024, the total accrued expenses due to related parties was $65,695, which includes $60,000 payable for administration fee and $5,695 payable for accounting related service fee. As of December 31, 2023, the total accrued expenses due to related parties was $25,250, which include $20,000 payable for administration fee and $5,250 payable for accounting service fee. See following paragraphs for details.

 

Initial Accounting Service Fee

 

The Company has engaged TenX Global Capital, a related party of the Company, to assist in the preparation of financial statements and other accounting consulting services.

 

This initial accounting service fee was only related with the initial accounting preparation which was incurred in the period from February 17, 2023 (inception) to September 30, 2023 with total amount of $20,000. There was no such cost in the subsequent periods.

 

Accounting Service Agreement

 

The Company has engaged TenX Global Capital, a related party of the Company, to assist in preparing quarterly and annual financial statements commencing following the consummation of the IPO. The Company has agreed to pay for these services at a fixed quarterly rate of $5,250 each quarter. For three months ended September 30, 2024 and 2023, service fees of $5,250 have been accrued for these services. For nine months ended September 30, 2024 and during the period from February 17, 2023 (inception) through September 30, 2023, service fee of $15,750 and $5,250 have been incurred for these services.

 

 

Administration Fee

 

Commencing on the effectiveness of the Registration Statement on July 11, 2023, an affiliate of the Sponsors will be allowed to charge the Company an allocable share of its overhead, up to $10,000 per month, until to the close of the Business Combination, to compensate it for the Company’s use of its office, utilities and personnel. Administration fee of $30,000 and $90,000 were incurred for the three and nine months ended September 30, 2024, respectively. For three months ended September 30, 2023 and the period from February 17, 2023 (inception) through September 30, 2023, an administration fee of $26,667 was recorded and paid.

 

v3.24.3
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, EBC founder shares, Private Placement Units will be entitled to registration rights pursuant to a registration rights agreement dated on the effectiveness of the Registration Statement on July 11, 2023 requiring the Company to register such securities for resale. Subject to certain limitations set forth in such agreement, the holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Business Combination Marketing Agreement

 

The Company has engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation of its initial Business Combination in an amount of $2,415,000, equal to 3.5% of the gross proceeds of the IPO. In addition, the Company will pay EBC a service fee in an amount equal to 1.0% of the total consideration payable in the initial Business Combination if it introduces the Company to the target business with whom it completes an initial Business Combination and the amount will be payable in cash and is due at the closing date of the initial Business Combination. EBC did not introduce the Company to Qianzhi.

 

 

Business Combination Transaction Cost

 

The Company has engaged several service providers including legal and valuation services, specifically for business combination between the Company and Shenzhen Qianzhi BioTechnology Co. Ltd. (“Qianzhi”). Per the agreed terms, Qianzhi agreed to be responsible for all expenses incurred by the Company in connection with business combination. During the three months ended September 30, 2024, $73,467 of business combination related cost has been incurred and reimbursed by Qianzhi. During the nine months ended September 30, 2024, $325,469 of business combination related cost has been incurred and reimbursed by Qianzhi. This activity has been recorded on the net basis and no impact to financial statements.

 

v3.24.3
SHAREHOLDERS’ EQUITY
9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
SHAREHOLDERS’ EQUITY

NOTE 7 — SHAREHOLDERS’ EQUITY

 

Preferred Shares — The Company is authorized to issue 2,000,000 preferred shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.

 

Ordinary Shares — The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. On February 27, 2023, the Sponsors received 1,725,000 of the Founder Shares in exchange for $25,000 paid for offering costs borne by the Sponsors, of which an aggregate of up to 225,000 of such Founder Shares were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company’s issued and outstanding ordinary shares after the IPO (excluding shares underlying the Private Placement Units). No ordinary shares are subject to forfeiture since the over-allotment was fully exercised on July 17, 2023. As of September 30, 2024 and December 31, 2023, there were 2,266,500 ordinary shares issued and outstanding (excluding 6,900,000 shares subject to possible redemption).

 

Rights — Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of the initial Business Combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-tenth (1/10) of one ordinary share underlying each right upon consummation of the business combination. If the Company is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.

 

v3.24.3
Fair Value Measurements
9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements

NOTE 8 — Fair Value Measurements

 

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

 

Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

 

 

Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

 

Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

 

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

 

 

Date  Trading Securities  Level   Fair Value 
September 30, 2024  Marketable securities held in the trust account   1   $74,534,487 
              
December 31, 2023  Marketable securities held in the trust account   1   $71,419,358 

 

v3.24.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Based upon this review, the Company identified the following subsequent event that would have required adjustment or disclosure in the financial statements.

 

Effective as of October 7, 2024, the Company notified the trustee of the Trust Account that it was extending the time to consummate an initial Business Combination from October 14, 2024 to January 14, 2025. Effective as of October 14, 2024, Shenzhen Qianzhi and EarlyBirdCapital, two designees of the Sponsors, loaned the Company an aggregate of $690,000, which funds were deposited into the Trust Account for such extension. The loans are evidenced by promissory notes (the “Notes”) issued by the Company to the designees. The Notes bear no interest and are repayable in full upon consummation of a Business Combination. In connection with the loans, one of the Sponsors transferred 30,000 of its Founder Shares to EarlyBirdCapital.   The value of the shares transferred is reflected as debt discount and fully amortized as interest expense over the life of the loan in accordance with ASC 835.

v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the period ended September 30, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024. All intercompany accounts and transactions are eliminated upon consolidation. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 29, 2024.

 

 

Emerging Growth Company

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had a cash balance of $271,847 and $426,913 as of September 30, 2024 and December 31, 2023, respectively. The Company had no cash equivalents as of September 30, 2024 and December 31, 2023.

 

Investments Held in Trust Account

Investments Held in Trust Account

 

The Company’s portfolio of investments held in the Trust Account is comprised of investments only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2024 and December 31, 2023, the Trust Account had balance of $74,237,487 and $71,419,358, respectively. The interest and dividend income earned from the Trust Account totaled $952,787 and $2,818,129 for three and nine months ended September 30, 2024, respectively, which were fully reinvested into the Trust Account as earned and unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Consolidated Statements of Cash Flows.

 

 

Offering Costs

Offering Costs

 

Offering costs consist of legal and other costs (including underwriting discounts and commissions) incurred through the balance sheet date that are directly related to the IPO and that were charged to shareholders’ equity upon the completion of the IPO on July 14, 2023.

 

Income Taxes

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2024 and December 31, 2023. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position.

 

There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements.

 

Net Income (Loss) per Ordinary Share

Net Income (Loss) per Ordinary Share

 

The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

 

 

The net income (loss) per share presented in the statements of operations is based on the following:

 

 

   2024  2023  September 30,
2024
  September 30,
2023
   Three Months Ended September 30,  Nine Months Ended  For the Period from February 17, 2023 through
   2024  2023  September 30,
2024
  September 30,
2023
Net income (loss)  $825,358   $573,444   $2,428,474   $570,338 
Accretion of temporary equity into redemption value (interest earned)   (952,787)   (760,871)   (2,818,129)   (760,871)
Accretion of temporary equity into redemption value   -      (7,520,591)   -      (7,520,591)
Net loss including accretion of equity into redemption value  $(127,429)  $(7,708,018)  $(389,655)  $(7,711,124)

 

 

   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
   For Three Months Ended
September 30, 2024
  For Nine Months Ended
September 30, 2024
  For Three Months Ended
September 30, 2023
  For the Period from
February 17, 2023 through
September 30, 2023
   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
Particulars   Shares    Shares    Shares    Shares    Shares    Shares    Shares    Shares 
Basic and diluted net income/(loss) per share:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Ownership percentage   75%   25%   75%   25%   73%   27%   55%   45%
Numerators:                                        
Allocation of net loss including accretion of temporary equity   (95,921)   (31,508)   (293,309)   (96,346)   (5,601,092)   (2,106,926)   (4,267,179)   (3,443,945)
Interest earned on investment held in trust account   952,787    -      2,818,129    -      760,871    -      760,871    -   
Accretion of temporary equity to redemption value   -      -      -      -      7,520,591    -      7,520,591    -   
Allocation of net income/(loss)   856,866    (31,508)   2,524,820    (96,346)   2,680,370    (2,106,926)   4,014,283    (3,443,945)
Denominators:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Basic and diluted net income/(loss) per share  $0.12   $(0.01)  $0.37   $(0.04)  $0.46   $(0.95)  $1.60   $(1.70)

 

 

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Ordinary Shares Subject to Possible Redemption

Ordinary Shares Subject to Possible Redemption

 

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

 

At September 30, 2024, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:

 

Public offering proceeds  $60,000,000 
Less:     
Proceeds allocated to Public Rights   (3,272,724)
Allocation of offering costs related to redeemable shares   (2,925,140)
Plus:     
Accretion of carrying value to redemption value   6,797,864 
Ordinary shares subject to possible redemption   60,600,000 
      
Over-allotment     
Plus:     
Over-allotment proceeds   9,000,000 
Less:     
Proceeds allocated to Public Rights   (490,909)
Allocation of offering costs related to redeemable shares   (212,727)
Plus:     
Accretion of carrying value to redemption value   793,636 
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   1,729,358 
Ordinary shares subject to possible redemption, December 31, 2023  $71,419,358 
Plus:     
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   2,818,129 
Ordinary shares subject to possible redemption, September 30, 2024  $74,237,487 

 

 

Recent Accounting Standards

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
SCHEDULE OF NET INCOME (LOSS) PER SHARE PRESENTED STATEMENTS OF OPERATIONS

 

   2024  2023  September 30,
2024
  September 30,
2023
   Three Months Ended September 30,  Nine Months Ended  For the Period from February 17, 2023 through
   2024  2023  September 30,
2024
  September 30,
2023
Net income (loss)  $825,358   $573,444   $2,428,474   $570,338 
Accretion of temporary equity into redemption value (interest earned)   (952,787)   (760,871)   (2,818,129)   (760,871)
Accretion of temporary equity into redemption value   -      (7,520,591)   -      (7,520,591)
Net loss including accretion of equity into redemption value  $(127,429)  $(7,708,018)  $(389,655)  $(7,711,124)
SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED

 

   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
   For Three Months Ended
September 30, 2024
  For Nine Months Ended
September 30, 2024
  For Three Months Ended
September 30, 2023
  For the Period from
February 17, 2023 through
September 30, 2023
   Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable  Redeemable  Non-Redeemable
Particulars   Shares    Shares    Shares    Shares    Shares    Shares    Shares    Shares 
Basic and diluted net income/(loss) per share:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Ownership percentage   75%   25%   75%   25%   73%   27%   55%   45%
Numerators:                                        
Allocation of net loss including accretion of temporary equity   (95,921)   (31,508)   (293,309)   (96,346)   (5,601,092)   (2,106,926)   (4,267,179)   (3,443,945)
Interest earned on investment held in trust account   952,787    -      2,818,129    -      760,871    -      760,871    -   
Accretion of temporary equity to redemption value   -      -      -      -      7,520,591    -      7,520,591    -   
Allocation of net income/(loss)   856,866    (31,508)   2,524,820    (96,346)   2,680,370    (2,106,926)   4,014,283    (3,443,945)
Denominators:                                        
Weighted-average shares outstanding   6,900,000    2,266,500    6,900,000    2,266,500    5,885,870    2,214,049    2,506,944    2,023,299 
Basic and diluted net income/(loss) per share  $0.12   $(0.01)  $0.37   $(0.04)  $0.46   $(0.95)  $1.60   $(1.70)
SCHEDULE OF ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION REFLECTED IN THE BALANCE SHEET

At September 30, 2024, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:

 

Public offering proceeds  $60,000,000 
Less:     
Proceeds allocated to Public Rights   (3,272,724)
Allocation of offering costs related to redeemable shares   (2,925,140)
Plus:     
Accretion of carrying value to redemption value   6,797,864 
Ordinary shares subject to possible redemption   60,600,000 
      
Over-allotment     
Plus:     
Over-allotment proceeds   9,000,000 
Less:     
Proceeds allocated to Public Rights   (490,909)
Allocation of offering costs related to redeemable shares   (212,727)
Plus:     
Accretion of carrying value to redemption value   793,636 
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   1,729,358 
Ordinary shares subject to possible redemption, December 31, 2023  $71,419,358 
Plus:     
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   2,818,129 
Ordinary shares subject to possible redemption, September 30, 2024  $74,237,487 
v3.24.3
RELATED PARTIES (Tables)
9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
SCHEDULE OF ASSUMPTIONS TO ESTIMATE FAIR VALUE

The fair value of the EBC founder shares was estimated at March 15, 2023. The Company used the following assumptions to estimate the fair value of EBC founder shares using Level 3 fair value measurements inputs at the measurement date:

 

 

Time to expiration   1.84 
Risk-free rate   4.0%
Volatility   5.0%
Dividend yield   0.0%
Probability of completion of business combination   60.0%
v3.24.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
SCHEDULE OF MEASURED FAIR VALUE ON RECURRING BASIS

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

 

 

Date  Trading Securities  Level   Fair Value 
September 30, 2024  Marketable securities held in the trust account   1   $74,534,487 
              
December 31, 2023  Marketable securities held in the trust account   1   $71,419,358 
v3.24.3
ORGANIZATION AND BUSINESS OPERATIONS (Details Narrative) - USD ($)
7 Months Ended 9 Months Ended
Jan. 18, 2024
Jul. 18, 2023
Jul. 17, 2023
Jul. 14, 2023
Sep. 30, 2023
Sep. 30, 2024
Oct. 07, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Ordinary shares, par value           $ 0.0001   $ 0.0001
Proceeds from issuance of private placement         $ 3,615,000    
Cash           271,847   $ 426,913
Working capital           12,879    
Merger Shares [Member] | Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of stock issued 7,246,377              
Earnout Shares [Member] | Agreement [Member] | Maximum [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of stock issued 1,400,000              
Subsequent Event [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Deposit into trust account             $ 690,000  
Subsequent Event [Member] | EarlyBirdCapital [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of shares transferred             30,000  
IPO [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of stock issued       6,000,000        
Ordinary shares, par value       $ 0.0001        
Price per share       $ 10.00        
Proceeds from issuance of IPO       $ 60,000,000   60,000,000    
Transaction cost   $ 3,318,898            
Cash underwriting fees   1,725,000            
Deposit into trust account   $ 1,593,898            
Private Placement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Price per share       $ 10.00        
Number of stock issued   31,500   330,000        
Proceeds from issuance of private placement       $ 3,300,000        
Over-Allotment Option [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of stock issued   900,000            
Price per share   $ 10.00            
Number of stock issued     900,000          
Proceeds from sale of units   $ 9,000,000            
Cash underwriting fees           $ 1,725,000    
Over-Allotment Option [Member] | Maximum [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of stock issued       900,000        
v3.24.3
SCHEDULE OF NET INCOME (LOSS) PER SHARE PRESENTED STATEMENTS OF OPERATIONS (Details) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Accounting Policies [Abstract]              
Net income (loss) $ (3,105) $ 825,358 $ 816,754 $ 786,362 $ 573,444 $ 570,338 $ 2,428,474
Accretion of temporary equity into redemption value (interest earned)   (952,787)     (760,871) (760,871) (2,818,129)
Accretion of temporary equity into redemption value       (7,520,591) (7,520,591)
Net loss including accretion of equity into redemption value   $ (127,429)     $ (7,708,018) $ (7,711,124) $ (389,655)
v3.24.3
SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Interest earned on investment held in trust account   $ 952,787     $ 760,871 $ 760,871 $ 2,818,129
Accretion of temporary equity to redemption value       7,520,591 7,520,591
Net income (loss) $ (3,105) $ 825,358 $ 816,754 $ 786,362 $ 573,444 $ 570,338 $ 2,428,474
Redeemable Shares [Member]              
Weighted average shares outstanding - basic   6,900,000     5,885,870 2,506,944 6,900,000
Weighted-average shares outstanding - diluted   6,900,000     5,885,870 2,506,944 6,900,000
Ownership percentage   75.00%     73.00% 55.00% 75.00%
Allocation of net loss including accretion of temporary equity   $ (95,921)     $ (5,601,092) $ (4,267,179) $ (293,309)
Interest earned on investment held in trust account   952,787     760,871 760,871 2,818,129
Accretion of temporary equity to redemption value       7,520,591 7,520,591
Net income (loss)   $ 856,866     $ 2,680,370 $ 4,014,283 $ 2,524,820
Basic net income/(loss) per share   $ 0.12     $ 0.46 $ 1.60 $ 0.37
Diluted net income/(loss) per share   $ 0.12     $ 0.46 $ 1.60 $ 0.37
Non Redeemable Shares [Member]              
Weighted average shares outstanding - basic   2,266,500     2,214,049 2,023,299 2,266,500
Weighted-average shares outstanding - diluted   2,266,500     2,214,049 2,023,299 2,266,500
Ownership percentage   25.00%     27.00% 45.00% 25.00%
Allocation of net loss including accretion of temporary equity   $ (31,508)     $ (2,106,926) $ (3,443,945) $ (96,346)
Interest earned on investment held in trust account      
Accretion of temporary equity to redemption value      
Net income (loss)   $ (31,508)     $ (2,106,926) $ (3,443,945) $ (96,346)
Basic net income/(loss) per share   $ 0.01     $ (0.95) $ (1.70) $ (0.04)
Diluted net income/(loss) per share   $ 0.01     $ (0.95) $ (1.70) $ (0.04)
v3.24.3
SCHEDULE OF ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION REFLECTED IN THE BALANCE SHEET (Details) - USD ($)
7 Months Ended 9 Months Ended
Jul. 14, 2023
Sep. 30, 2023
Sep. 30, 2024
Subsidiary, Sale of Stock [Line Items]      
Ordinary shares subject to possible redemption     $ 71,419,358
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)   $ 760,871 2,818,129
Ordinary shares subject to possible redemption     74,237,487
IPO [Member]      
Subsidiary, Sale of Stock [Line Items]      
Public offering proceeds $ 60,000,000   60,000,000
Proceeds allocated to Public Rights     (3,272,724)
Allocation of offering costs related to redeemable shares     (2,925,140)
Accretion of carrying value to redemption value     6,797,864
Ordinary shares subject to possible redemption     60,600,000
Over-Allotment Option [Member]      
Subsidiary, Sale of Stock [Line Items]      
Proceeds allocated to Public Rights     (490,909)
Allocation of offering costs related to redeemable shares     (212,727)
Accretion of carrying value to redemption value     793,636
Over-allotment proceeds     9,000,000
Subsequent measurement of ordinary shares subject to possible redemption (income earned on trust account)     $ 1,729,358
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 7 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Dec. 31, 2023
Accounting Policies [Abstract]          
Cash $ 271,847     $ 271,847 $ 426,913
Cash equivalents 0     0 0
Trust account balance 74,237,487     74,237,487 71,419,358
Interest and dividend income earned from trust account 952,787 $ 760,871 $ 760,871 2,818,129  
Unrecognized tax benefits 0     0 0
Interest and penalties accrued 0     0 $ 0
Cash FDIC insured amount $ 250,000     $ 250,000  
v3.24.3
INITIAL PUBLIC OFFERING (Details Narrative) - USD ($)
9 Months Ended
Jul. 18, 2023
Jul. 14, 2023
Sep. 30, 2024
Subsidiary, Sale of Stock [Line Items]      
Nasdaq entry fee     $ 75,000
IPO [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock issued during the period, shares   6,000,000  
Sale of stock, par share   $ 10.00  
Units related to initial public offering description   Each Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. Ten Public Rights will entitle the holder to one ordinary share (see Note 7). The Company will not issue fractional shares and only whole shares will trade, so unless a holder purchased units in multiples of tens, such holder will not be able to receive or trade the fractional shares underlying the rights  
Over-Allotment Option [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock issued during the period, shares 900,000    
Sale of stock, par share $ 10.00    
Over-Allotment Option [Member] | Maximum [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock issued during the period, shares   900,000  
v3.24.3
PRIVATE PLACEMENTS (Details Narrative) - USD ($)
1 Months Ended
Jul. 18, 2023
Jul. 14, 2023
Mar. 15, 2023
Feb. 27, 2023
Mar. 31, 2023
Subsidiary, Sale of Stock [Line Items]          
Value of stock issued         $ 1,016,000
Sponsors [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued       1,725,000  
Value of stock issued       $ 25,000  
EBC [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued     180,000    
Unit exercise price per share     $ 0.014    
Value of stock issued     $ 2,520    
Private Placement [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued 31,500 330,000      
Unit exercise price per share   $ 10.00      
Value of stock issued   $ 3,300,000      
Units related to private placement description   Each Private Placement Unit consists of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination.      
Private Placement [Member] | Sponsors [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued   312,000      
Private Placement [Member] | EBC [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued   18,000      
Private Placement [Member] | Underwriters [Member]          
Subsidiary, Sale of Stock [Line Items]          
Number of shares issued   361,500      
Value of stock issued   $ 3,615,000      
v3.24.3
SCHEDULE OF ASSUMPTIONS TO ESTIMATE FAIR VALUE (Details)
Mar. 15, 2023
Platform Operator, Crypto Asset [Line Items]  
Time to expiration 1 year 10 months 2 days
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Risk Free Interest Rate [Member]  
Platform Operator, Crypto Asset [Line Items]  
Founder shares measurement input 4.0
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member]  
Platform Operator, Crypto Asset [Line Items]  
Founder shares measurement input 5.0
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Expected Dividend Rate [Member]  
Platform Operator, Crypto Asset [Line Items]  
Founder shares measurement input 0.0
Fair Value, Inputs, Level 3 [Member] | Measurement Input, Probability of Completion of Business Combination [Member]  
Platform Operator, Crypto Asset [Line Items]  
Founder shares measurement input 60.0
v3.24.3
RELATED PARTIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended
Jul. 18, 2023
Jul. 17, 2023
Jul. 14, 2023
Jul. 11, 2023
Mar. 15, 2023
Feb. 27, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Dec. 31, 2023
Value of stock issued             $ 1,016,000          
Administrative fee               $ 30,000 $ 26,667 $ 26,667 $ 90,000  
Accounting Service Agreement [Member]                        
Accounting service fee               5,250 $ 5,250 5,250 15,750  
Payment for services               5,250        
Ten X Global Capital [Member]                        
Accounting service fee                   $ 20,000    
Related Party [Member]                        
Accrued expenses               65,695     65,695 $ 25,250
Related Party [Member] | General and Administrative Expense [Member]                        
Accrued expenses               60,000     60,000 20,000
Related Party [Member] | Accounting Services Expense [Member]                        
Accrued expenses               5,695     $ 5,695 $ 5,250
Promissory Note [Member] | Sponsors [Member]                        
Debt Instrument, Face Amount           $ 300,000            
Debt Instrument, Maturity Date           Jul. 14, 2023            
Over-Allotment Option [Member]                        
Number of stock issued   900,000                    
Number of units sold 900,000                      
Cash underwriting discount per unit                     $ 0.25  
Aggregate cash underwriting discount                     $ 1,500,000  
Cash underwriting fees                     1,725,000  
Sale of stock price per unit $ 10.00                      
Proceeds from sale of units $ 9,000,000                      
Over-Allotment Option [Member] | Maximum [Member]                        
Number of units sold     900,000                  
IPO [Member]                        
Number of units sold     6,000,000                  
Cash underwriting fees $ 1,725,000                      
Sale of stock price per unit     $ 10.00                  
IPO [Member] | Sponsors [Member]                        
Due to related party               $ 151,318     $ 151,318  
Sponsors [Member]                        
Number of stock issued           1,725,000            
Value of stock issued           $ 25,000            
Sponsors [Member] | Maximum [Member]                        
Affiliate costs per month       $ 10,000                
Sponsors [Member] | Over-Allotment Option [Member]                        
Number of shares subject to forfeiture           225,000            
EBC [Member]                        
Number of stock issued         180,000              
Value of stock issued         $ 2,520              
Ordinary share price         $ 0.014              
Fair value of shares issued         $ 1,016,000              
Fair value of ordinary per share price         $ 5.65              
v3.24.3
COMMITMENTS AND CONTINGENCIES (Details Narrative)
3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2024
USD ($)
Qianzhi [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Business combination related cost incurred $ 73,467 $ 325,469
Business Combination Marketing Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Business combination related cost incurred   $ 2,415,000
Percentage of gross proceeds of initial public offering 3.50% 3.50%
Percentage of service fee of total consideration payable 1.00% 1.00%
v3.24.3
SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Jul. 17, 2023
Feb. 27, 2023
Mar. 31, 2023
Sep. 30, 2024
Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Preferred stock, shares authorized       2,000,000 2,000,000
Preferred stock, par value       $ 0.0001 $ 0.0001
Preferred stock, shares issued       0 0
Preferred stock, shares outstanding       0 0
Ordinary stock, shares authorized       200,000,000 200,000,000
Ordinary stock, par value       $ 0.0001 $ 0.0001
Ordinary stock, voting rights       each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination  
Issuance of ordinary shares to Sponsor, value     $ 1,016,000    
Ordinary stock, shares issued       2,266,500 2,266,500
Ordinary stock, shares outstanding       2,266,500 2,266,500
Ordinary shares subject to redemption       6,900,000 6,900,000
Over-Allotment Option [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Issuance of ordinary shares to Underwriter, shares 900,000        
Sponsors [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Issuance of ordinary shares to Underwriter, shares   1,725,000      
Issuance of ordinary shares to Sponsor, value   $ 25,000      
Sponsors [Member] | Over-Allotment Option [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Number of shares subject to forfeiture   225,000      
Common Stock [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Ordinary stock, voting rights       Holders of ordinary shares are entitled to one vote for each share  
Issuance of ordinary shares to Underwriter, shares     180,000    
Issuance of ordinary shares to Sponsor, value     $ 18    
v3.24.3
SCHEDULE OF MEASURED FAIR VALUE ON RECURRING BASIS (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in the trust account $ 74,237,487 $ 71,419,358
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities held in the trust account $ 74,534,487 $ 71,419,358
v3.24.3
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]
Oct. 07, 2024
USD ($)
shares
Subsequent Event [Line Items]  
Deposits | $ $ 690,000
EarlyBirdCapital [Member]  
Subsequent Event [Line Items]  
Number of shares transferred | shares 30,000

Bowen Acquisition (NASDAQ:BOWNU)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Bowen Acquisition Charts.
Bowen Acquisition (NASDAQ:BOWNU)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Bowen Acquisition Charts.